Small cell lung cancer

• Evaluation of the safety and efficacy of the drug AL8326 in the post-first treatment of small cell lung cancer. Not authorised
  2023-509067-24-00 4 "Small Cell Lung Cancer (SCLC) patients who need ≥2nd line tr"
• A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has … Pending
  2025-522288-13-00 4 "Patients with pretreated extensive-stage small cell lung can"
• A Phase 1/2 Study of BMS-986525 with and without Nivolumab in Relapsed/Refractory Small Cell Lung Cancer Pending
  2025-524090-16-00 7 "Relapsed/Refractory Small Cell Lung Cancer"
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting
  2025-521639-34-00 3 2026-04-20 "• Non-small cell lung cancer (Stage III, unresectable) • Sma"
• A Phase 1 Study to Determine the Safety, Tolerability and Pharmacokinetics of 177Lu-EVG321 in Patients with Small Cell Lung Cancer Recruiting
  2024-518039-12-00 1 2025-05-27 "Small Cell Lung Cancer"
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 "Large cell neuroendocrine carcinoma"
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 "Small Cell Lung Cancer (SCLC)"
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab … Recruiting
  2024-517490-24-00 4 2026-03-31 "Small Cell Lung Cancer"
• A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity … Recruiting
  2025-523165-19-00 1 2026-02-10 "Advanced, metastatic or unresectable solid tumors"
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 "English First-line extensive-stage small-cell lung cancer (E"
• Durvalumab after definitive chemoradiotherapy in limited stage small cell lung cancer Recruiting
  2025-521340-37-00 5 2025-07-24 "small cell lung cancer"
• A clinical study of MK-6070 and ifinatamab deruxtecan in people with small cell lung cancer (MK-6070-002) Recruiting
  2024-517926-25-00 9 2025-03-12
• A Phase 2 diagnostic study with 68Ga-EVG321 in Patients with Small Cell Lung Cancer Recruiting
  2024-514584-25-00 4 2024-12-16 "Small Cell Lung Cancer"
• A Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated … Recruiting
  2024-514446-36-00 1 2024-11-21 "Small Cell Lung Cancer"
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 "Advanced PRAME Positive Cancers"
• A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF … Recruiting
  2022-502092-33-00 4 2024-05-31 "Extensive-disease small cell lung cancer and high SLFN11-exp"
• Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell … Recruitment ended
  2023-509067-24-01 4 2025-06-17 "- Small Cell Lung Cancer (SCLC) patients who need ≥2nd line "
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Recruitment ended
  2024-516051-40-00 4 2025-06-10 "Small Cell Lung Cancer (SCLC)"
• Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe Recruitment ended
  2023-503574-20-00 4 2023-11-29 "Lung Cancer"
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Recruitment ended
  2024-515047-31-00 5 2023-08-28 "Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)"
• PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR A … Recruitment ended
  2024-515492-34-00 9 2023-03-30 "Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC an"
• A study of PF-08046050 (SGN-CEACAM5C) in adults with advanced solid tumors Halted
  2023-505858-18-00 1 2024-06-28 "Pancreatic carcinoma"
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG … Ended
  2023-503996-38-00 1 2025-05-21 "Advanced or metastatic solid tumors"
• A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Particip … Ended
  2024-516907-18-00 3 2024-11-20 "Small cell lung cancer, Castration-resistant prostate cancer"

Showing 1–24 of 35 trials